Abstract:Recent researches showed patient-derived organoids (PDO) could recapitulate main features of the primary tumors, and could be used as in vitro clinical model to predictive outcome in clinical setting. Here, we have launched the observational investigation to prove whether the PDO radiosensitivity could predict the clinical outcome in locally advanced rectal cancer (LARC) patients (pts) underwent neo-adjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC). Primary tumor tissues of LARC pts for PDO culture were collected by rectal biopsy before any treatment. Rectal cancer cells were isolated and cultured following established protocols for PDO culture and expansion. PDOs were exposed to 8Gy X-rays at 246 cGy/min, 5-fluorouracil (10μM) and CPT-11 (10μM), respectively, and PDO images were captured every 3 days in the following 24 days. PDO radiosensitivity and drugs sensitivity was determined by ROC area changes. Tumor response to neoadjuvant therapy was evaluated according to the pathological tumor regression grading (TRG). Finally, PDO radiosensitivity and drug sensitivity data compared with clinical patients outcome. We established 34 rectal adenocarcinoma organoids from 40 pts with 85% success rate. RCO data showed 23, 25 and 17 pts’ organoids were resistant, while 11, 9 and 13 pts’ organoids were sensitive to irradiation, 5-fluorouracil and CPT-11 treatment, respectively. All of the 34 pts received surgery (total mesorectal excision) and got the pathologic TRG data, or achieved clinical complete response (cCR). Clinical data showed 19 pts achieved good response (TRG=0 or 1, or cCR), and other 15 pts had poor response (TRG= 2 or 3). Through comparative analysis, RCO radiosensitivity and drug sensitivity (5-fluorouracil and CPT-11) were concordant with clinical outcome in 76.5% (26/34), 70.6% (24/34) and 70 % (21/30) pts, respectively. In consideration of combined treatment in clinic, chemoradiation responses in patients are highly matched to RCO responses, with 86.70 % sensitivity, 94.70% specificity, 92.90 % positive predict value, 90.0 % negative predict value and 91.20 % accuracy. The patient-derived organoids’ radiosensitivity correlates to clinical outcome and indicated that organoid model may be used to predict TRG and prognosis in LARC patients receiving nCRT. PDO may be potentially used as a biomarker to for treatment stratification and worth study further.

A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases

Patient-Derived Organoids (Pdo) As The Potential Model To Predict Treatment Outcome Of Rectal Cancer Patients Underwent Neo-Adjuvant Chemoradiotherapy

Patient‐Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy

Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer

Additional File 2 of A Novel Patient-Derived Organoids-Based Xenografts Model for Preclinical Drug Response Testing in Patients with Colorectal Liver Metastases

389PThe establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

The Establishment of Patient-Derived Organoid Models and Drug Response of Resectable Non-Small Cell Lung Cancer

Establishing A Patient-Derived Colorectal Cancer Xenograft Model For Translational Research

Colorectal Cancer Tissue-Originated Spheroids Reveal Tumor Intrinsic Signaling Pathways and Mimic Patient Clinical Chemotherapeutic Response As a Rapid and Valid Model

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Genomic characteristics and drug screening among organoids derived fromnon-small celllung cancer patients

Patient-derived micro-organospheres enable clinical precision oncology

The combination of breast cancer PDO and mini‐PDX platform for drug screening and individualized treatment

Patient-derived organoids and mini-PDX for predicting METN375S-mutated lung cancer patient clinical therapeutic response

Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

"Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction"

Patient-derived organoids of non-small cells lung cancer and their application for drug screening

Indirect in vivo Mini patient-derived xenograft models to reproduce the effect of drug response of tumors in metastatic colorectal cancer

Colorectal Cancer Organoid Models Uncover Oxaliplatin-Resistant Mechanisms at Single Cell Resolution